Author's response to reviews

Title: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomised, double-blind, placebo-controlled 102-week trial

Authors:

Clifford J Bailey (c.j.bailey@aston.ac.uk)
Jorge L Gross (jorgeluizgross@gmail.com)
Delphine Hennicken (delphine.hennicken@bms.com)
Nayyar Iqbal (nayyar.iqbal@bms.com)
Traci A Mansfield (traci.mansfield@bms.com)
James F List (james.list@bms.com)

Version: 3 Date: 16 January 2013

Author's response to reviews:

We are pleased to submit the revised version of this manuscript. As requested, we have generated p-values for the outcomes in Tables 1 and 3 and have provided them in the manuscript. The following additional changes were made in the body of the manuscript:

On page 9, we added a sentence about the significance of the change in serum uric acid levels, and we revised the statement about the EMA to note that dapagliflozin is now approved in the European Union.

On page 12 at the end of the Discussion section, we added the phrase between asterisks:

The mean decreases in serum uric acid observed with dapagliflozin here and in other trials, *which are consistent with the uricosuric action of this agent,* might therefore indicate potential added benefits, but this requires further investigation.

Again, we appreciate your consideration of this article for publication in BMC Medicine.

Cliff Bailey